ORIGINAL RESEARCH article
Front. Med.
Sec. Regulatory Science
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1570817
This article is part of the Research TopicRegulatory Science: Addressing Uncertainties in Medicines Development, Evaluation and UseView all 8 articles
Measuring the Multidimensional Reputation of a Medicines Regulatory Agency: Development and Validation of a Public-Oriented Scale
Provisionally accepted
- Hanyang Universiy, Erica, Ansan, Gyeonggi, Republic of Korea
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: The reputation of public agencies, encompassing the dimensions of performance, morality, procedure, and technical competence, is fundamental to understanding their behavior. However, standardized, individual-level measures of reputation suitable for surveys targeting the general public are lacking. This study aims to develop and validate a survey instrument for the general public to measure the multi-dimensional reputation of public agencies, with a focus on South Korea's medicines regulatory agency.Methods: Survey items were developed based on previous literature, refined through expert consultation, and validated through a population survey. The validation study involved 1,000 participants from the public, selected using a quota sampling method stratified by age, sex, and region, according to the South Korean census. Validity was assessed through exploratory factor analysis and hypothesis testing, while reliability was evaluated using internal consistency.Results: Exploratory factor analysis identified a three-dimensional structure of reputation, encompassing performance, procedure, and technical competence, while morality was not distinctly identified as a separate dimension. Construct validity, including convergent and discriminant validity, was confirmed. The internal consistency of the three dimensions was acceptable, with Cronbach's alpha coefficients ranging from 0.87 to 0.91. The overall reputation of the medicines regulatory agency was measured at 72 out of 100. The specific dimension scores were as follows: 74 for technical competence, 71 for performance, and 70 for procedure.Conclusions: The agency should recognize the multidimensional nature of reputation and foster an environment that enables the public to observe and evaluate these dimensions. Reputation management strategies should emphasize not only technical expertise but also performance and procedural aspects to ensure a well-rounded reputation.
Keywords: Medicines regulatory agency, reputation, Development scale, Validation, South Korea
Received: 04 Feb 2025; Accepted: 31 Mar 2025.
Copyright: © 2025 Son. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Kyung-Bok Son, Hanyang Universiy, Erica, Ansan, 15588, Gyeonggi, Republic of Korea
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.